Welcome to the dedicated Spotlight On Policy page, your central resource for curated, expert-driven coverage of pharmaceutical and health system policy across the United States, the United Kingdom, Europe, and the wider global landscape. US Policy updates Market Access US pharma MFN and tariff dynamics: What EU and UK leaders ne... Europe and the United Kingdom are entering a period of direct exposure to US policy choices, and the implications are significant and immediate. News Trump's affordability plan arrives, built around MFN pricing Trump has finally delivered his healthcare proposals, but it seems the 'concept of a plan' promised for many years remains pretty much just that. News Novartis issues a life sciences warning in a 'G-Zero' world Novartis claims life sciences lie at the centre of a shift in geopolitics and policies in regions like Europe, Japan, and Canada are "self-defeating." News EMA and FDA agree 'principles' for AI in drug development The FDA and EMA have come up with guiding principles that they say will underpin future guidance on the use of AI technologies in drug development. more EU Policy updates Market Access US pharma MFN and tariff dynamics: What EU and UK leaders ne... Europe and the United Kingdom are entering a period of direct exposure to US policy choices, and the implications are significant and immediate. News Novartis issues a life sciences warning in a 'G-Zero' world Novartis claims life sciences lie at the centre of a shift in geopolitics and policies in regions like Europe, Japan, and Canada are "self-defeating." News EMA and FDA agree 'principles' for AI in drug development The FDA and EMA have come up with guiding principles that they say will underpin future guidance on the use of AI technologies in drug development. Market Access ISPOR Glasgow with EVERSANA: Perspectives on JCA, PICO, and ... At ISPOR EU 2025, a cross-stakeholder panel addressed how Joint Clinical Assessment under the EU HTA Regulation is reshaping evidence strategies. more UK Policy updates Market Access US pharma MFN and tariff dynamics: What EU and UK leaders ne... Europe and the United Kingdom are entering a period of direct exposure to US policy choices, and the implications are significant and immediate. News Novartis issues a life sciences warning in a 'G-Zero' world Novartis claims life sciences lie at the centre of a shift in geopolitics and policies in regions like Europe, Japan, and Canada are "self-defeating." Market Access Changes to UK’s VPAG: Non-submissions should be a key metric... Whatever people think of changes to the UK’s pricing deal, VPAG, judging the difference they make should include monitoring non-submissions to NICE. News UK names health data chief, as BIA finds its new CEO Dr Melanie Ivarsson has been appointed head of the UK's new Health Data Research Service, as the BIA selects Prof Chris Molloy as its new CEO. more
Market Access US pharma MFN and tariff dynamics: What EU and UK leaders ne... Europe and the United Kingdom are entering a period of direct exposure to US policy choices, and the implications are significant and immediate.
News Trump's affordability plan arrives, built around MFN pricing Trump has finally delivered his healthcare proposals, but it seems the 'concept of a plan' promised for many years remains pretty much just that.
News Novartis issues a life sciences warning in a 'G-Zero' world Novartis claims life sciences lie at the centre of a shift in geopolitics and policies in regions like Europe, Japan, and Canada are "self-defeating."
News EMA and FDA agree 'principles' for AI in drug development The FDA and EMA have come up with guiding principles that they say will underpin future guidance on the use of AI technologies in drug development.
Market Access US pharma MFN and tariff dynamics: What EU and UK leaders ne... Europe and the United Kingdom are entering a period of direct exposure to US policy choices, and the implications are significant and immediate.
News Novartis issues a life sciences warning in a 'G-Zero' world Novartis claims life sciences lie at the centre of a shift in geopolitics and policies in regions like Europe, Japan, and Canada are "self-defeating."
News EMA and FDA agree 'principles' for AI in drug development The FDA and EMA have come up with guiding principles that they say will underpin future guidance on the use of AI technologies in drug development.
Market Access ISPOR Glasgow with EVERSANA: Perspectives on JCA, PICO, and ... At ISPOR EU 2025, a cross-stakeholder panel addressed how Joint Clinical Assessment under the EU HTA Regulation is reshaping evidence strategies.
Market Access US pharma MFN and tariff dynamics: What EU and UK leaders ne... Europe and the United Kingdom are entering a period of direct exposure to US policy choices, and the implications are significant and immediate.
News Novartis issues a life sciences warning in a 'G-Zero' world Novartis claims life sciences lie at the centre of a shift in geopolitics and policies in regions like Europe, Japan, and Canada are "self-defeating."
Market Access Changes to UK’s VPAG: Non-submissions should be a key metric... Whatever people think of changes to the UK’s pricing deal, VPAG, judging the difference they make should include monitoring non-submissions to NICE.
News UK names health data chief, as BIA finds its new CEO Dr Melanie Ivarsson has been appointed head of the UK's new Health Data Research Service, as the BIA selects Prof Chris Molloy as its new CEO.
